A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine
| Autor: | Jemima S. A. Dzator, Peter R. C. Howe, Kirsten G. Coupland, Rachel H. X. Wong |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Cross-Over Studies Nutrition and Dietetics Migraine Disorders Headache resveratrol phytoestrogen nutrient intervention cerebrovascular function hormonal migraine prophylaxis migraine disability assessment Treatment Outcome Double-Blind Method Resveratrol Dietary Supplements Quality of Life Humans Female Food Science |
| Zdroj: | Nutrients; Volume 14; Issue 9; Pages: 1763 |
| ISSN: | 2072-6643 |
| DOI: | 10.3390/nu14091763 |
| Popis: | Resveratrol, a vasoactive phytoestrogen, has beneficial effects on cerebrovascular function. Previous research has shown that hormonal migraineurs have poorer cerebrovascular function than non-migraineur women. We aimed to investigate if resveratrol supplementation for three months could reduce the hormonal migraine burden index (HMBI: the number of days with menstrual migraine per month), reduce migraine-related disability and improve migraine-related quality of life. A randomised, double-blind, placebo-controlled, crossover, intervention trial was conducted in 62 hormonal migraineurs (mean age: 37.5 ± 0.8 years). Participants consumed 75 mg of resveratrol or matching placebo capsules twice daily for three months before crossing over to the other treatment arm. Participants completed a daily diary and the Headache Impact Test-6™, Migraine Disability Assessment and Migraine-Specific Quality of Life questionnaires at months 0, 3 and 6. The HMBI was the primary outcome and was calculated using data extracted from the participant’s diary. No differences in the HMBI (p = 0.895), the Headache Impact Test-6™, the Migraine Disability Assessment and Migraine-Specific Quality of Life were found between the resveratrol and placebo treatments. Resveratrol supplementation for three months did not affect the HMBI, the migraine-related disability or quality of life measures in our cohort of hormonal migraineurs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|